More tools:Markets·Screener·Research·Chat

Standard BioTools Inc. Common Stock (LAB) Financial Statements

Standard BioTools Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001T0FDP3
XNAS · usd
0.69▲ 0.01 (0.95%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close0.69
Day's Range0.67 – 0.73
52-Week Range0.63 – 1.72
Volume2.8M
Avg Volume1.8M
Share Statistics
Shares Outstanding
Employees389
ExchangeXNAS
Listed2011-02-10
Share count as of August 3, 2026
Loading Income Statement…
Key questions about Standard BioTools Inc. Common Stock (LAB)
What is Standard BioTools Inc. Common Stock's Market Cap?
Standard BioTools Inc. Common Stock's Market Cap is $271.7M, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's Trailing P/E?
Standard BioTools Inc. Common Stock's Trailing P/E is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's Price / Sales?
Standard BioTools Inc. Common Stock's Price / Sales is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's Revenue (TTM)?
Standard BioTools Inc. Common Stock's Revenue (TTM) is $84.6M, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's Net Income (TTM)?
Standard BioTools Inc. Common Stock's Net Income (TTM) is $84.9M, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's EBITDA?
Standard BioTools Inc. Common Stock's EBITDA is -$90.0M, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's Diluted EPS (TTM)?
Standard BioTools Inc. Common Stock's Diluted EPS (TTM) is 0.22, based on as-reported figures from SEC (XBRL) filings.
What is Standard BioTools Inc. Common Stock's EBITDA Margin?
Standard BioTools Inc. Common Stock's EBITDA Margin is -106.3%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-7.6%+4.6%-4.0%-11.5%
Cost of revenue:
Total cost of revenue
Gross profit
% of revenue52.4%53.5%47.8%48.5%
Operating expenses:
Research and development
Selling, general and administrative
Restructuring and related charges
Transaction and integration expenses
Total operating expenses
% of revenue178.7%112.6%151.4%217.0%
Loss from continuing operations
% of revenue-126.3%-59.1%-103.6%-168.5%
Interest income, net
Other (expense) income, net
Loss from continuing operations before income taxes
Income tax benefit
Net loss from continuing operations
Net (loss) income
% of revenue-133.1%600.9%81.0%-177.4%
Net income (loss) per share, basic (in dollars per share)
Net (loss) income per share attributable to common stockholders, basic and diluted